This marks a turning point where longevity science meets consciousness science. The question is no longer only “can psychedelics heal?” but “can they influence how long and how deeply we live?” His first trip is Sunday, November 9. We'll follow up when he does!

High-dose mushroom trips often leads to less fear, more acceptance, more awe around mortality. The transformation isn’t about escaping death—it’s about understanding it more deeply.

But the bigger question isn’t biological. It’s what happens when someone who wants to defeat death takes a dose known for reshaping our relationship with death.

One reason he’s doing this? Science has begun to hint at psilocybin's role in cellular aging. Studies show human cells living 50% longer after psilocin exposure, and mice seeing longer lifespans and fewer aging markers.

249 biomarkers before and after each dose: DNA methylation, inflammation, hormones, microbiome, vascular aging, mitochondrial health, neurocognition, fertility, and more. He’s not just asking how it feels. He’s asking what it changes.

Psychedelic research tends to measure mood, anxiety, or mental health outcomes. He’s measuring biology itself, down to the deepest systems that govern aging.

On Sunday, November 9, his experiment takes an unexpected turn. He starts a 3-month protocol: one 5g magic mushroom trip per month, measured with extreme biological precision.

Bryan Johnson has built his life around one goal: defeat biological aging and extend human lifespan. He tracks every variable imaginable to prove aging can be engineered, quantified, and eventually overcome.

Bryan Johnson (@bryan_johnson) is launching a 5g psilocybin longevity experiment measured across 249 biomarkers. But this experiment goes much deeper than that... 🧵 Here's why everyone is so intrigued...

If adopted, Maryland’s plan could become the national blueprint for evidence-based psychedelic reform — proving that science, safety, and compassion can coexist in policy.

An accompanying analysis from Johns Hopkins University projects that psilocybin therapy could serve 2,500–9,000 Marylanders per year, with up to $20 million in annual consumer spending once established. Unlike other states, the task force isn’t waiting on federal approval to

Their approach focuses on public safety, equity, and education — aiming to make access broad, affordable, and responsibly managed. It’s called the “ensemble model,” and it blends medical, supervised, and community-based frameworks into one coordinated system.

The Maryland Task Force on Responsible Use of Natural Psychedelic Substances — chaired by Dr. Andrew Coop of the University of Maryland School of Pharmacy — just released its final report. It lays out a multi-phase plan that begins with psilocybin therapy, expands to supervised

Maryland just dropped a bold, science-backed roadmap that could one day lead to legal psilocybin therapy. 🧵 Here's the potential plan...

Here are the studies mentioned: 📄 Johns Hopkins & NYU: https://t.co/36ZbcC22RG 📄 Zurich: https://t.co/B1pTqCoZPx 📄 Australia: https://t.co/c3ce0gvZc2 📄 UCSF:

Access to this kind of care should not be a privilege — it should be a basic human right. No government or institution should have the power to decide what someone can or cannot do with their own consciousness, especially at the end of life. Everyone deserves the chance to

This is where science meets spirit — where medicine remembers its heart. These therapies help people meet death not with resistance, but with understanding. They offer the rarest form of healing: peace, connection, and love in life’s final moments.

And this isn’t just happening in the U.S. In Switzerland, LSD-assisted psychotherapy at the University of Zurich brought safe, lasting relief from anxiety and fear. In Australia, psilocybin therapy at St. Vincent’s Hospital in Melbourne helped patients rediscover meaning and

Family members described witnessing something extraordinary — their loved ones laughing, smiling, and calm in their final days. They weren’t afraid anymore. One described it as seeing “a light come back into them.” That kind of peace isn’t found in medicine alone. It’s

At Johns Hopkins and NYU, researchers gave psilocybin to patients with terminal cancer in carefully guided therapeutic settings. Over 80% experienced profound reductions in anxiety and depression that lasted for months — and in many cases, until their final days. Many called it